Next 10 |
2024-05-17 15:00:04 ET More on the markets SPY: Time To Be Contrarian And Underweight SPY ETF: Momentum Is In The Cards SPY: Get Ready For A Recessionary Bear Market DWS is cautiously optimistic about stocks, but expects 'jittery' market Investors pur...
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and confe...
2024-05-08 20:28:08 ET Supernus Pharmaceuticals, Inc. (SUPN) Q1 2024 Earnings Conference Call May 08, 2024 04:30 PM ET Company Participants Peter Vozzo - ICR Westwicke, Investor Relations Jack Khattar - Chief Executive Officer Tim Dec - Chief Financial Officer ...
2024-05-08 16:56:17 ET More on Supernus Pharmaceuticals Supernus Pharmaceuticals: Moving Through An 'Inflection Year' Supernus stock slides as FDA rejects Parkinson's disease infusion device Seeking Alpha’s Quant Rating on Supernus Pharmaceuticals Hist...
Net sales of Qelbree ® increased 75% to $45.1 million compared to first quarter 2023. Total revenues were $143.6 million. Total revenues excluding Trokendi XR ® and Oxtellar XR ® net product sales (non-GAAP) (1) increased 12% to $100.7 million compared to first ...
2024-05-07 17:20:52 ET More on Supernus Pharmaceuticals Supernus Pharmaceuticals: Moving Through An 'Inflection Year' Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Call Transcript Supernus stock slides as FDA rejects Parkinson's disease infusion device ...
Busy is getting candid about navigating her ADHD diagnosis and treatment experience with Qelbree ® The percentage of women newly diagnosed with ADHD between 23-29 and 30-49 years of age nearly doubled in just two years (2020-2022) 1 Although symptoms are present in childhoo...
ROCKVILLE, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it expects to report financial and busi...
2024-04-14 23:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-08 12:00:03 ET Irene Buhalo from Jefferies issued a price target of $40.00 for SUPN on 2024-04-08 10:10:00. The adjusted price target was set to $40.00. At the time of the announcement, SUPN was trading at $32.265. SUPN currently trades -16.55% versus its 52 week...
News, Short Squeeze, Breakout and More Instantly...
Supernus Pharmaceuticals Inc. Company Name:
SUPN Stock Symbol:
NASDAQ Market:
Supernus Pharmaceuticals Inc. Website:
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing...
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company will hold a webcast and confe...
Net sales of Qelbree ® increased 75% to $45.1 million compared to first quarter 2023. Total revenues were $143.6 million. Total revenues excluding Trokendi XR ® and Oxtellar XR ® net product sales (non-GAAP) (1) increased 12% to $100.7 million compared to first ...